

## REFERENCES :

### BILIARY CANCER

1. Valle J, Wasan H, Palmer DH, et al Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. for the ABC-02 Trial Investigators N Engl J Med 2010; 362:1273-1281 .
2. Maithel SK, Gamblin TC, Kamel I, et al Multidisciplinary approaches to intrahepatic cholangiocarcinoma.. Cancer. 2013 Aug 20.
3. Matsuo K, Rocha FG, Ito K, D'Angelica MI, et al. The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg. 2012 Sep;215(3):343-55.
4. Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012 Feb;13(2):181-8.
5. Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.Br J Cancer. 2008(2):309-15.
6. Eckmann KR, Patel DK, Landgraf A, et al Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis.. Gastrointest Cancer Res. 2011 Sep;4(5-6):155-60.
7. Jensen LH Biliary-tract cancer: improving therapy by adding molecularly targeted agents..Lancet Oncol. 2012 Feb;13(2):118-9.
8. Andersen JB, Spee B, Blechacz BR, et al.Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.. Gastroenterology. 2012 Apr;142(4):1021-1031.
9. Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.Nat Genet. 2013 Dec;45(12):1470-3.

### PANCREATIC ADENOCARCINOMA

1. Katz MH, Wang H, Fleming JB, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009; 16: 836-847.
2. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.. Ann Surg 2001; 234: 758-768.
3. Oettle H, Post S, Neuhaus P, et al. Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerA Randomized Controlled Trial. JAMA. 2007;297(3):267-277.
4. Katz MH, Marsh R, Herman JM, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013; 20: 2787-2795.

5. Birkmeyer JD, Warshaw AL, Finlayson SR et al. Relationship between hospital volume and late survival after pancreaticoduodenectomy. *Surgery* 1999; 126: 178-183.
6. Evans DB, Varadhachary GR, Crane CH et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. *J Clin Oncol* 2008; 26: 3496-3502.
7. Katz MH, Pisters PW, Evans DB et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. *J Am Coll Surg* 2008; 206: 833-846; discussion 846-838.
8. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011; 364: 1817-1825.
9. Von Hoff DD, Ervin TJ, Arena FP et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). *N Engl J Med*. 2013 (18):1691-703.
10. Mukherjee S, Hurt CN, Bridgewater J et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. *Lancet Oncol* 2013; 14: 317-326.
11. Iacobuzio-Donahue, C.A., et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. *J Clin Oncol*. 2009; 27(11): p. 1806-13.
12. Florence Huguet, Pascal Hammel, Dewi Vernerey, et al. Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 4001)

## CARCINOMA OF UNKNOWN PRIMARY

1. Briasoulis E, Tolis C, Bergh J, et al.. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP), *Ann Oncol* 2005;16;Suppl 1:i75–i76.
2. National Comprehensive Cancer Network; Occult Primary (Cancer of Unknown Primary) 2013;version 1.;[www.nccn.org](http://www.nccn.org).
3. Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. *Cancer* 2004;101:2641–9.
4. Rudmik L, Lau HY, Matthews TW, et al. Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: A prospective clinical trial. *Head Neck*. 2011;Jul;33;7:935-40. doi: 10.1002/hed.21566. Epub 2010 Nov 12.
5. Randall DA, Johnstone PA, Foss RD, et al. Tonsillectomy in diagnosis of the unknown primary tumor of the head and neck. *Otolaryngol Head Neck Surg* 2000;122:52–5.
6. Moller AK, Loft A, Berthelsen AK, et al. 18F-FDG PET/CT as a diagnostic tool in patients with extracervical carcinoma of unknown primary site: a literature review. *Oncologist*. 2011;16;4:445-51. Epub 2011 Mar 22.
7. DeYoung BR, Wick MR. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach, *Semin Diagn Pathol* 2000;17:184–193.
8. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. *Clin Cancer Res*. 2005;11:3766-72.

9. Varadhachary GR, Spector Y, Abbruzzese JL, et al. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. *Clin Cancer Res.* 2011;17:4063-70.
10. Oien KA, Dennis JL. Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling. *Ann Oncol.* 2012;23:271-7.
11. Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute. *J Clin Oncol.* 2013;31:217-23
12. Varadhachary GR, Raber MN, Matamoros A, et al. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. *Lancet Oncol.* 2008;6:596-9.
13. Culine S, Kramar A, Saghatchian M, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. *J Clin Oncol.* 2002;24:4679-83.
14. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. *J Clin Oncol* 2000;18:3101-7.
15. Weiss L, Chu P, Schroeder BE, et al. Immunohistochemistry (IHC) vs a 92-Gene Cancer Classifier in the Diagnosis of Primary Site in Metastatic Tumors: A Blinded Comparator Study. *J Mol Diagn.* 2012;14:721 (abstract:ST96)
16. Varadhachary GR, Raber MN. Cancer of unknown primary site. *N Engl J Med.* 2014 Aug 21;371(8):757-65